Obesity 2020-Jul
The potential benefit of telmisartan to protect overweight COPD patients from the acquisition of COVID-19
רק משתמשים רשומים יכולים לתרגם מאמרים
התחבר הרשם
הקישור נשמר בלוח
מילות מפתח
תַקצִיר
Individuals with chronic obstructive pulmonary disease (COPD) have long been identified to have an elevated serum level of angiotensin-converting enzyme 2 (ACE2), the cellular entry receptor for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The newest discoveries by Higham et al. (1) were the increased ACE2 expression in the bronchial epithelium of overweight COPD patients compared to their non-overweight counterparts.